Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C)
Authors:
- Henning BreithauptHBHenning Breithaupt
- Hans PralleHPHans Pralle
- Thomas EckhardtTEThomas Eckhardt
- Michael Von HattingbergMHMichael Von Hattingberg
- Jürgen SchickJSJürgen Schick
Open Access
Abstract
Four patients with acute nonlymphoblastic leukemia and one malignant teratoma refractory to conventional chemotherapy were treated with high doses of cytosine arabinoside (HD ARA-C). They received up to 12 cycles of 1.8 to 3 g/m2 every 12 hours applied by 2-hour infusions. A total of 55 HD ARA-C infusions was performed. All leukemic patients responded. A complete clearance of blasts from the bone marrow was observed in two patients following 8–12 cycles of 3 g/m2. However, relapses occurred after three and seven weeks, in one case with resistance to HD ARA-C. The patient with malignant teratoma did not respond. No severe toxicity emerged even after repeated applications. Adverse reactions included moderate nausea and vomiting (4 patients), diarrhea (2 patients), hepatic dysfunction (1 patient), bone pain (1 patient), blurred vision (1 patient), conjunctivitis (1 patient), and exanthema with partial epidermiolysis (1 patient). Granulocytopenia occurring between 3–8 days after having started the therapy, subsided within 4–25 days. Plasma levels of ARA-C and the metabolite uracil arabinoside (ARA-U) were monitored. At steady state plasma concentrations of ARA-C were 32–97 μM (8–24 μ/ml). ARA-C disappeared from the plasma mono- or biphasic with a terminal half-life (t50%) of 7.8–12.6 minutes. The total clearance (Cl) or ARA-C varied between 1.7 and 2.9 liters/kg · h, and the distribution volume (Vss) between 0.44 and 0.86 liters/kg. Cerebrospinal fluid (CSF) levels of ARA-C reached 10–15% of steady state concentrations in plasma.Keywords
This publication has 13 references indexed in Scilit:
- Determination of cytarabine and uracil arabinoside in human plasma and cerebrospinal fluid by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1981
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979
- Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.British Journal of Clinical Pharmacology, 1979
- Pharmacokinetics of cytosine arabinoside in acute myeloid leukemiaClinical Pharmacology & Therapeutics, 1977
- Acute Granulocytic LeukemiaArchives of internal medicine (1960), 1976
- Drugs Five Years LaterAnnals of Internal Medicine, 1975
- Mechanisms of Resistance of Human Acute Leukaemia Cells to Cytosine ArabinosideBritish Journal of Haematology, 1974
- Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosineClinical Pharmacology & Therapeutics, 1971
- Cytidine Deaminase and the Development of Resistance to Arabinosyl CytosineNature New Biology, 1971
- Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinosideBiochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 1968